A phase 2 study shows that the oral Janus kinase (JAK) 1 inhibitor abrocitinib quickly improved atopic dermatitis (AD) severity and symptoms versus placebo with some measures achieving statistically significant separation in days.
New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium.
With extended remissions, high safety and favorable dosing schedules, interleukin (IL)-23 inhibitors are well-suited for a variety of patients with psoriasis, says an expert who spoke at the South Beach Symposium
Susan C. Taylor, M.D., shares distinguishing characteristics of differential diagnoses to keep in mind when examining skin of color patients for rosacea.
It's thought that rosacea affects about 10% of the population, but this estimation may not be completely accurate as the condition is often underdiagnosed – especially in individuals with darker skin types.
Platelet-rich plasma (PRP) shows promise as an adjunctive treatment for atrophic acne scarring, but experts say more research is needed.
Several new studies indicate that disease burden may be higher in adolescents than in adults with atopic dermatitis, and that adolescents with moderate-to-severe disease may face an even greater unmet therapeutic need.
A Danish study suggests that TNF inhibitors may not increase the risk of developing recurring or new primary cancers in patients with inflammatory diseases.
Ustekinumab’s short-term effect on aortic vascular inflammation points to possible role of IL-12, IL-23 in cardiovascular disease, but more research is needed.
A web-based survey indicates erythema severity correlates with rosacea’s quality-of-life impact.